Asthma is a heterogeneous lung disorder characterized by airway obstruction, inflammation and eosinophil infiltration into the lung. Both genetics and environmental factors influence the expression of asthma, and not all asthma is the result of a specific immune response to allergen. Numerous asthma phenotypes have been described, including occupational asthma, and therapeutic strategies for asthma control are similar regardless of phenotype. We hypothesized that mechanistic pathways leading to asthma symptoms in the effector phase of the disorder differ with the inciting allergen. Since route of allergen exposure can influence mechanistic pathways, mice were sensitized by identical routes with a high molecular weight occupational allergen ovalbumin and a low molecular weight occupational allergen trimellitic anhydride (TMA). Different statistical methods with varying selection criteria resulted in identification of similar candidate genes. Array data are intended to provide candidate genes for hypothesis generation and further experimentation. Continued studies focused on genes showing minimal changes in the TMA-induced model but with clear up-regulation in the ovalbumin model. Two of these genes, arginase 1 and eotaxin 1 are the focus of continuing investigations in mouse models of asthma regarding differences in mechanistic pathways depending on the allergen. Microarray data from the ovalbumin and TMA model of asthma were also compared to previous data using Aspergillus as allergen to identify putative asthma 'signature genes', i.e. genes up-regulated with all 3 allergens. Array studies provide candidate genes to identify common mechanistic pathways in the effector phase, as well as mechanistic pathways unique to individual allergens.
Introduction
An estimated 300 million people are affected by asthma world-wide (1) with varying percentages of the population affected in different countries. Estimates of the prevalence of asthma range from 2% in Greece and 6% in Japan to as many as 15% in New Zealand. The economic burden of asthma is substantial and includes both direct costs (hospitalization and medication) and indirect costs (days lost from work and reduced quality of life). Numerous phenotypes of asthma have been described, and a better understanding of the pathophysiological mechanisms of different asthma phenotypes, including occupational asthma, can provide the basis for more targeted treatment of this heterogeneous lung disorder. This review will focus on occupational asthma and experiments done in animal models pointing to mechanistic differences in the effector phase of asthma depending on the inciting allergen.
What is Asthma?
Asthma is a lung disorder characterized by symptoms of cough, wheezing and chest tightness. These symptoms are attributed to the development of reversible airway obstruction, inflammation, airway hyperresponsiveness and mucus production. An operational definition of asthma developed by experts in the field (1) describes major attributes of the disorder. "Asthma is a chronic inflammatory disorder of the airways in which many cells play a role, in particular mast cells, eosinophils, and T lymphocytes. In susceptible individuals this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and cough particularly at night and/or in the early morning. These symptoms are usually associated with widespread but variable airflow limitation that is at least partly reversible either spontaneously or with treatment. The inflammation also causes an associated increase in airway responsive-ness to a variety of stimuli." Clearly this definition of asthma does not include a cause. Both host factors (genetics) and environmental factors are known to influence the development and expression of asthma, and a vast array of triggers of asthma have been identified. Various asthma phenotypes have been described in attempts to better define the lung disorder. Wenzel in a recent review (2) proposed three phenotypic categories of asthma: Clinical or physiological phenotypes, phenotypes related to trigger, and inflammatory phenotypes. Clinical or physiological phenotypes are based on descriptors such as the severity of the disease (mild, moderate, severe) or the age of onset (child, adult). Phenotypes related to trigger are based on exposures that initiate the asthmatic symptoms (aspirininduced, exercise-induced, occupational, etc.), and inflammatory phenotypes rely on a pathophysiological description (eosinophilic, neutrophilic, etc.) . The variety of descriptions of asthma phenotypes indicates the heterogeneity of asthma and the uncertainty in the field regarding the cause of asthma. The heterogeneity of clinical symptoms under the umbrella of asthma has indeed prompted some experts to suggest that we abandon asthma as a disease concept (3). Debate also continues regarding the best measure of asthma control (4), inflammation or pulmonary function. Asthma therapies target both the inflammatory component (steroids) and the airway obstruction component (bronchodilators). Asthma control may also differ with the asthma phenotype. A recent study found that children with a severe asthma phenotype had less airflow obstruction compared to adults with severe asthma (5) suggesting that antiinflammatory therapy may be more critical for asthma control in the phenotype of childhood asthma.
Currently, therapeutic management of asthma is the same whether an individual is allergic to dust mites, toluene diisocyanate, or cat dander. However, different allergens may contribute to asthma heterogeneity or different asthma phenotypes by initiating unique mediator pathways leading to the asthma symptoms. Improved understanding of the effector mechanisms initiated by different allergens will help determine how best to tailor asthma treatment in the individual.
What is Occupational Asthma?
Occupational asthma is asthma caused by workplace exposure (6). This is distinguished from pre-existing asthma that is exacerbated by workplace exposures. Occupational asthma is further subdivided into occupational asthma with (allergic) or without (non-allergic) a latency period. During the latency period of allergic asthma, a specific immune response to the allergen occurs, without asthma symptoms being manifested. Non-allergic asthma does not require a latency period for symptoms to be apparent and by inference does not involve a specific immune response to the offending substance. Irritantinduced asthma is considered a subset of non-allergic occupational asthma. Some occupational asthma to irritating chemicals may be a combination of allergic and non-allergic asthma. Allergic asthma is most amenable to modeling in animals so studies of occupational asthma have primarily investigated the pathophysiology of allergic occupational asthma following sensitization and challenge with occupational allergens. Occupational allergens are generally categorized as either high or low molecular weight allergens. Examples of high molecular weight occupational allergens include proteases used in the detergent industry, laboratory animal allergens, and ovalbumin (OVA) exposure in egg processing facilities (7-9). Low molecular weight allergens are generally reactive chemicals that act as haptens. Diisocyanates (10) and acid anhydrides (11) are known low molecular weight allergens that cause occupational asthma.
Use of microarrays to identify novel effector mechanisms
In allergic asthma two phases are considered: the sensitization or induction phase and the challenge or effector phase. In the sensitization phase during the latent period, a specific immune response occurs in response to allergen exposure. No asthma symptoms are manifested. After a specific immune response to allergen, whether chemical or protein, re-exposure to the allergen can result in the symptoms of asthma, the effector phase. With the advent of microarray technology, rapid determination of changes in gene expression during the effector phase became possible. This technique allows widespread screening and identification of many genes not previously implicated in the allergic response. For example, it was generally believed that the complement system was not involved in effector mechanisms in allergy because complement activation is not triggered by IgE antibody associated with allergic diseases. However, Karp et al. (12) used microarray analysis of pulmonary gene expression and single nucleotide polymorphism-based genotyping, combined with quantitative trait locus analysis to determine that the complement component C5 was associated with allergen induced airway hyperresponsiveness to OVA as the allergen. For this analysis, A/J mice that easily develop allergen induced airway hyperresponsiveness were crossed with C3H/HeJ mice to obtain new mouse strains. Zimmermann et al. (13) also capitalized on microarray techniques to identify genes that were up-regulated in the lungs of mice sensitized and challenged with either the allergen OVA or Aspergillus. This 'discovery science' identified arginase, trefoil factor-2, small proline rich protein 2, ADAM 8, and other novel genes as potentially important genes in the asthmatic response. Many of the candidate genes were not classically associated with allergic respiratory responses. The identification of arginase 1 from array studies in a mouse model led to identification of increased arginase in lung tissue from human asthmatics as well (13). Following initial identification by array analysis, continued studies have begun a more detailed analysis of the expression and regulation of some of these candidate genes in allergen or IL-13 induced inflammation and airway hyperresponsiveness in mouse models (14-17). Rigorous experiments to implicate these molecules as critical to the allergen induced symptoms in mouse models of asthma have not yet been done.
